Applications of 2-(4-Boc-Piperazinyl)-2-Phenylacetic Acid in Industrial Manufacturing

2-(4-Boc-Piperazinyl)-2-Phenylacetic Acid is an essential intermediate in the synthesis of advanced pharmaceuticals and specialty chemicals. As the direct manufacturer, we supply high-purity grade product to support complex, multi-step production pipelines in regulated industries. Below, we detail the principal application fields based on real industrial practice, covering compliance requirements, formulation specifics, process role, and the resulting commercial products.

1. API Intermediate Synthesis for CNS Drug Development

This compound is integral in the stepwise construction of central nervous system (CNS) active pharmaceutical ingredients, specifically in piperazine-based molecular scaffolds for antipsychotic and antidepressant drug candidates. Downstream pharmaceutical companies employ it in reaction sequences where strict control of raw material purity yields safe, effective final APIs compatible with modern CNS therapies. Our production ensures reliable supply chain continuity and batch-to-batch consistency required for late-stage process validation campaigns.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopeia 11.0 (relevant monograph sections)
• FDA 21 CFR Part 211 Current Good Manufacturing Practice (cGMP)
• Chinese Pharmacopoeia ChP 2025 (for API sourcing)

Typical usage ratio

• Applied at 1.2–1.5 molar equivalents per target conversion, depending on the alkylation or amidation step and downstream scale-up throughput; process R&D adjusts this range based on reaction efficiency and impurity carryover risk.

Downstream process integration

• Introduced during the protected piperazine ring functionalization stage—typically after Boc-protection and before amidation or coupling—using solvent-phase or continuous flow synthesis; feeds directly to catalyst-mediated condensation or cyclization units.

Final product types

• Antipsychotic bulk APIs (e.g., aripiprazole, brexpiprazole intermediates)
• Antidepressants with piperazine motifs
• CNS-active research chemical entities
• Regulated API reference standards

2. Protected Piperazine Derivatives for Oncology Compound Synthesis

As a protected carboxylic acid-bearing piperazine, this material is a foundational building block in constructing kinase inhibitor and cytotoxic drug molecules. Chemical process engineers depend on its consistent protection profile to achieve regioselective transformations required for heterocyclic oncology drugs, where side reactions must remain tightly controlled to pass rigorous impurity profiles during new drug application (NDA) filings.

Industry compliance standards

• USP General Chapter <1086> Impurities in New Drug Substances
• European Medicines Agency (EMA) ICH M7 guideline (mutagenic impurities)
• Good Laboratory Practice (GLP) for intermediate QC
• NMPA Process Validation Guidance (PRC)

Typical usage ratio

• Utilized at 0.8–1.1 parts per 1 part of next-stage coupling agent; ratio tuned according to route design (solid-phase vs. solution-phase synthesis) and the specific kinase target molecule.

Downstream process integration

• Incorporated immediately following Boc-activation, introduced into amide coupling steps, and deprotected in final or penultimate stages prior to linker attachment or ring closure within oncology compound development pipelines.

Final product types

• Tyrosine kinase inhibitor bulk intermediates
• Peptidomimetic cytotoxic agent precursors
• Oncology research compounds for biologics conjugation
• Early-phase small molecule drug candidates

3. Building Block for Custom Peptide/Peptidomimetic Manufacturing

This acid-functionalized piperazine structure is frequently adopted by custom peptide houses and peptide API process developers as a specialty monomer for N-terminal modification or side-chain engineering. It enables precise insertion of piperazine units that confer unique metabolic stability or bioavailability enhancements in therapeutic peptides and peptidomimetics. Our technical grade is controlled to minimize extraneous amine/carbonyl impurities which can otherwise compromise downstream solid-phase yields.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• ISO 9001:2015 Quality Management (peptide synthesis suppliers)
• FDA 21 CFR Part 210/211 (where APIs produced as peptides)
• Synthesizer vendor process validation (for automated platforms)

Typical usage ratio

• Introduced at 1–3% w/w of resin load in standard peptide solid-phase synthesis (SPPS); exact loading depends on sequence complexity and the number of intended piperazine insertions.

Downstream process integration

• Coupling occurs during SPPS chain elongation (Fmoc-strategy compatible); the raw material’s carboxylic acid group reacts with free amines on resin-bound peptides via carbodiimide or uronium-type activation, followed by Boc-deprotection as required.

Final product types

• Therapeutic peptide APIs with metabolic stabilizing modifications
• Diagnostic and imaging peptide conjugates
• Peptidomimetic research series
• Pharma-grade peptide reference materials

4. Fine Chemical Intermediate for Chiral Auxiliary Synthesis

Specialty chemical manufacturers utilize this molecule in the construction of chiral auxiliaries for asymmetric catalysis, particularly where piperazine backbones impart unique steric or electronic control. Its Boc-protected amine group is leveraged in multi-step syntheses leading to custom auxiliaries used in stereoselective reductions and alkylations. Our manufacturing process supports tight release specifications for key impurity types (chlorinated residuals, Boc cleavage byproducts) to align with demanding auxiliary performance requirements.

Industry compliance standards

• ISO 14001 Environmental Management (chemical production)
• REACH regulation (EC) No 1907/2006 registration
• Responsible Care chemical handling practices
• Customer-specific Certificate of Analysis (CoA) release testing to < 0.3% total impurities

Typical usage ratio

• Incorporated at 0.2–0.5 molar equivalents per chiral auxiliary unit; precise quantities engineered based on auxiliary design and catalytic efficiency criteria established in the customer’s synthetic protocol.

Downstream process integration

• Typically reacts at early stages of multi-step synthesis for chiral ligands; following initial protection, the compound’s piperazine ring is functionalized or ligated onto core skeletons, eventually yielding chiral auxiliaries for downstream asymmetric reactions.

Final product types

• Chiral catalyst auxiliaries for fine chemical synthesis
• Asymmetric reduction agents
• Specialty ligands for transition metal catalysis
• Chemical standards for chiral method development